Tu1350 Usefulness of Lewis Score of Capsule Endoscopy in Japanese Patients With Crohn's Disease

Abstract

and then had received scheduled maintenance IFX. Similarly, in the Re-set IFX group, patients received scheduled maintenance IFX immediately following surgery to eliminate active CD lesions. Both groups were followed for 3 to 5 years during which patients’ disease profiles were monitored with a keen interest in mucosal healing. Results: During 1, 2 and 5 years of follow up, remission maintenance rates were 58.3%, 37.5%, and 16.2%, respectively in the RIFX group. The corresponding maintenance remission rates in the Re-set IFX group were 91.7%, 69.5% and 51.7%. Likewise, complete mucosal healing rate at 3 years was 29.6% in the RIFX group and 75.0% in the Re-set IFX group, reflecting vastly better maintenance efficacy rates in the Re-set IFX group vs RIFX group. Readmission rate was 50.0% in the RIFX group vs 21.2% in the Re-set IFX group, while re-operation rate was 23.3% in the RIFX group and 12.1% in the Re-set IFX group. Conclusions: In the clinical settings described above, scheduled maintenance IFX therapy appeared to produce improved efficacy outcomes when initiated immediately after resections of active CD lesions. More notably, the efficacy of IFX to induce mucosal healing was better in the Re-set treatment setting vs routine setting.